Ziccum’s CEO Ann Gidner delivered a presentation at BioStock 2024 Global Forum on May 30th, 2024 in Lund, Sweden, outlining the disruptive potential of LaminarPaceTM, a formulation and drying technology for delicate liquid biologics.
LaminarPaceTM is a unique formulation and drying technology for biopharmaceuticals and vaccines based on mass transfer, reducing drying stress on the active ingredient. By solving stability issues and enabling entirely new delivery options, such as inhalation even of the most delicate mRNA/LNP composition, it is opening up novel therapeutic avenues for targeting numerous indications for previously unmet needs.
Please watch the full presentation here to learn more about LaminarPaceTM, its excellent mRNA activity preservation data, animal study milestone results, and an overview of Ziccum’s technology licensing business model: Ziccum | BioStock Global Forum 2024 (youtube.com)